osaterone acetate

Osaterone acetate is used in veterinary medicine for the treatment of benign prostatic hyperplasia (BPH) in dogs. It has been found to produce remission of clinical symptoms of BPH in 83% of dogs for six months after a single one-week course of treatment,{{cite book| vauthors = Cote E |title=Clinical Veterinary Advisor: Dogs and Cats|url=https://books.google.com/books?id=NmziBQAAQBAJ&pg=PA848|date=9 December 2014|publisher=Elsevier Health Sciences|isbn=978-0-323-24074-1|pages=848–}} and can be used long-term.

Osaterone acetate comes in the form of 1.875 mg, 3.75 mg, 7.5 mg, and 15 mg oral tablets for veterinary use.

Side effects of osaterone acetate include diminished sperm quality (for up to 6 weeks post-treatment), transient elevation of liver enzymes (caution should be observed with known liver disease), vomiting, diarrhea, polyuria/polydipsia, lethargy, and hyperplasia of the mammary glands. It can also decrease cortisol levels, interfere with adrenocorticotropic hormone response, induce or exacerbate adrenal insufficiency, and exacerbate diabetes mellitus.{{cite book| vauthors = Ettinger SJ, Feldman EC |title=Textbook of Veterinary Internal Medicine|url=https://books.google.com/books?id=4Qzau1jagOYC&pg=PA2055|date=24 December 2009|publisher=Elsevier Health Sciences|isbn=978-1-4377-0282-8|pages=2055–}}{{cite book | vauthors = Lamm C, Makloski C |title=Theriogenology, An Issue of Veterinary Clinics: Small Animal Practice|url=https://books.google.com/books?id=gtoRaSR2NxcC&pg=PT112|date=28 May 2012|publisher=Elsevier Health Sciences|isbn=978-1-4557-4447-3|pages=112–}}

Osaterone acetate is a steroidal antiandrogen, progestin, and antigonadotropin. It has virtually no estrogenic or androgenic activity. Its side-effect profile indicates that it possesses clinically relevant glucocorticoid activity. An active metabolite of osaterone acetate, 15β-hydroxyosaterone acetate, has potent antiandrogenic activity similarly to osaterone acetate. Osaterone acetate treats BPH in dogs by reducing the actions of androgens in the prostate gland.

The major active metabolite of osaterone acetate is 15β-hydroxyosaterone acetate. Osaterone acetate has a long biological half-life of 80 hours to 197 ± 109 hours in dogs.{{cite book| vauthors = Maddison JE, Page SW, Church D |title=Small Animal Clinical Pharmacology|url=https://books.google.com/books?id=RpsROVqemk8C&pg=PA536|year=2008|publisher=Elsevier Health Sciences|isbn=978-0-7020-2858-8|pages=536–}}

{{See also|Steroidal antiandrogen|List of steroidal antiandrogens|List of progestogens|Progestogen ester|List of progestogen esters}}

Osaterone acetate, also known as 2-oxachloromadinone acetate, as well as 17α-acetoxy-6-chloro-2-oxa-6-dehydroprogesterone or 17α-acetoxy-6-chloro-2-oxapregna-4,6-diene-3,20-dione, is a synthetic pregnane steroid and a derivative of progesterone and 17α-hydroxyprogesterone. It is a derivative of the less potent chlormadinone acetate. The medication is the C17α acetate ester of osaterone.

Osaterone acetate was approved for veterinary use in the European Union under the brand name Ypozane in 2007.{{cite journal | vauthors = Emmerich IU, Ungemach FR | title = Neue Arzneimittel für Kleintiere 2007 | journal = Tierärztliche Praxis Ausgabe K: Kleintiere/Heimtiere. | date = 2008 | volume = 36 | issue = 5 | pages = 311–22 | doi = 10.1055/s-0038-1622691 | s2cid = 257184365 }}

Osaterone acetate is the generic name of the drug.{{cite web | title = Osaterone | url = https://www.drugs.com/international/osaterone.html | work = Drugs.com }} Osaterone is the {{abbrlink|INN|International Nonproprietary Name}} of the deacetylated parent compound.

Osaterone acetate is marketed under the brand name Ypozane by Virbac throughout the European Union.

Osaterone acetate was also investigated in Japan in the treatment of prostate cancer and BPH in humans but was ultimately never marketed for such purposes.{{cite book | vauthors = Schröder FH, Radlmaier A | chapter = Steroidal Antiandrogens | pages = 325–346 | doi = 10.1007/978-1-59259-152-7_15 | title = Hormone Therapy in Breast and Prostate Cancer | series = Cancer Drug Discovery and Development | veditors = Jordan VC, Furr BJ | year = 2009 | publisher = Humana Press | isbn = 978-1-60761-471-5}}

{{Reflist}}

{{refbegin}}

• {{cite book | vauthors = Schröder FH, Radlmaier A |title=Hormone Therapy in Breast and Prostate Cancer|chapter=Steroidal Antiandrogens|series=Cancer Drug Discovery and Development |year=2009|pages=325–346|publisher=Humana Press |doi=10.1007/978-1-59259-152-7_15|isbn=978-1-60761-471-5}}

{{refend}}

{{Navboxes

| title = Medical uses

| titlestyle = background:#ccccff

| list1 =

{{Drugs used in benign prostatic hypertrophy}}

{{Androgens and antiandrogens}}

{{Progestogens and antiprogestogens}}

}}

{{Navboxes

| title = Pharmacodynamics

| titlestyle = background:#ccccff

| list1 =

{{Androgen receptor modulators}}

{{Progesterone receptor modulators}}

{{Glucocorticoid receptor modulators}}

}}

{{Portal bar | Medicine}}

{{Authority control}}

Category:Acetate esters

Category:Antiandrogen esters

Category:Antigonadotropins

Category:Dog medications

Category:Drugs for benign prostatic hyperplasia

Category:Glucocorticoids

Category:Hepatotoxins

Category:Lactones

Category:Organochlorides

Category:Pregnanes

Category:Progestogen esters

Category:Progestogens

Category:Steroidal antiandrogens